StockNews.com lowered shares of LivaNova (NASDAQ:LIVN – Free Report) from a strong-buy rating to a buy rating in a report released on Thursday.
A number of other analysts have also weighed in on the company. The Goldman Sachs Group began coverage on LivaNova in a report on Friday, October 4th. They set a “buy” rating and a $65.00 target price for the company. Mizuho decreased their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Robert W. Baird lifted their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, Needham & Company LLC restated a “buy” rating and issued a $75.00 target price on shares of LivaNova in a research note on Monday, November 25th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, LivaNova has a consensus rating of “Buy” and a consensus target price of $69.17.
Read Our Latest Analysis on LivaNova
LivaNova Trading Down 1.4 %
Insider Buying and Selling at LivaNova
In other news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.27% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On LivaNova
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Nordea Investment Management AB boosted its holdings in shares of LivaNova by 22.2% in the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock valued at $3,188,000 after acquiring an additional 12,470 shares during the last quarter. Driehaus Capital Management LLC grew its holdings in LivaNova by 64.7% during the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after acquiring an additional 213,749 shares during the period. Harbor Capital Advisors Inc. acquired a new position in LivaNova in the fourth quarter valued at approximately $1,954,000. Perceptive Advisors LLC boosted its position in LivaNova by 48.5% in the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock worth $24,340,000 after purchasing an additional 145,000 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of LivaNova by 3.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company’s stock valued at $41,889,000 after purchasing an additional 25,277 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Stories
- Five stocks we like better than LivaNova
- How to Use the MarketBeat Dividend Calculator
- Bloom Energy: Powering the Future With Decentralized Energy
- High Flyers: 3 Natural Gas Stocks for March 2022
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Do ETFs Pay Dividends? What You Need to Know
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.